Shots:
Driven by innovations and propelled by the pursuit of delivering the best-in-class therapies, 2023 remained a good year for the Biopharma Industry, despite a slight revenue decline, partly due to the conclusion of the COVID-19 pandemic
With a CAGR of 7.8 %, the global biopharma industry is anticipated to register a market size of…
